Ami Organics Q4 Review - Focus Remains On Technology Upgradation, Process Improvement: KRChoksey

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..KRChoksey Research Report.During Q4 FY22, Ami Organics Ltd. reported revenue of Rs 1,435 million (up 54.47% YoY / up 1.70% QoQ). For FY22 topline was up by 52.70% YoY. The growth was driven by pharma intermediate business followed by specialty chemicals post acquisition of facilities from Gujrat Organics Ltd.On operational front Ami Organics' Ebitda in Q4 FY22 stood at Rs 258 million (up 10.78% YoY) but dipped marginally on QoQ basis by 13.57%, operating profit margin saw a dip of 709 basis points YoY and 318 bps QoQ to 17.98% in Q4 FY22. Margins fell on account of rising input costs. Net profit in Q4 FY22 stood at Rs 213 million showing an improvement of 38.31% YoY and 9.23% QoQ, with net profit margin at 14.94%, marginal impact of 173 bps on YoY basis and improved 102 bps on QoQ basis. .Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Ami Organics Q4 Review - Focus Remains On Technology Upgradation, Process Improvement: KRChoksey

Ami Organics Q4 Review - Focus Remains On Technology Upgradation, Process Improvement: KRChoksey

Choose a plan